Global Anti-malarial Drugs Market Size study, by Drug Class, Malaria Type, and Mechanism of Action and Regional Forecasts 2022–2032

Global Anti-malarial Drugs Market is valued approximately at USD 0.98 billion in 2023 and is anticipated to grow with a moderate but promising CAGR of more than 4.26% over the forecast period 2024–2032. In the enduring fight against malaria, anti-malarial drugs serve as critical lifelines for millions of people in endemic regions across the globe. These therapeutics are engineered to either eliminate the parasite after infection or prevent it from developing in the human body altogether. The expanding footprint of climate-sensitive mosquito-borne diseases, coupled with cross-border population migration and inadequate sanitation infrastructure, has elevated the urgency for advanced, accessible, and durable anti-malarial treatment protocols.

Recent years have seen a revival in innovation pipelines, driven by international funding coalitions and public-private partnerships such as Medicines for Malaria Venture (MMV) and WHO-led eradication roadmaps. Drug development has leaned toward novel artemisinin-based combination therapies (ACTs) and next-generation antifolates aimed at combating Plasmodium falciparum and emerging drug-resistant strains. Pharmaceutical companies are also exploring single-dose and long-acting agents that can curtail compliance issues in vulnerable populations. However, concerns over growing parasite resistance and high R&D costs pose significant challenges to both scalability and market penetration.

The market is not just shaped by treatment dynamics but also by the growing use of anti-malarials for prophylactic applications among travelers, military personnel, and humanitarian workers. There's increasing focus on the stratification of treatment based on malaria species—P. falciparum, P. vivax, P. malariae, and P. ovale—due to their varying virulence, recurrence patterns, and geographical spread. Moreover, the demand for pediatric and pregnant-safe formulations is prompting players to diversify product portfolios while ensuring regulatory compliance across emerging economies with high disease burdens.

Regionally, Africa continues to dominate the anti-malarial drugs market, being the epicenter of the global malaria burden. Countries such as Nigeria and the Democratic Republic of Congo account for a disproportionately high percentage of global cases, making them hotspots for treatment and prevention interventions. Asia Pacific is also expanding rapidly due to intensified governmental campaigns in India, Myanmar, and Indonesia, alongside heightened deployment of ACTs. Meanwhile, Latin America is witnessing re-emergence pockets in countries like Venezuela and Brazil due to migration-linked transmission. North America and Europe maintain steady market shares primarily through prophylactic sales and research activities driven by traveler-based demand and institutional collaborations.

Major market player included in this report are:
• Novartis AG
• Cipla Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Mylan N.V.
• Pfizer Inc.
• Ipca Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Zydus Lifesciences Limited
• Strides Pharma Science Ltd.
• Hikma Pharmaceuticals PLC
• Torrent Pharmaceuticals Ltd.

The detailed segments and sub-segment of the market are explained below:

By Drug Class
• Aryl Amino Alcohol Compounds
• Antifolate Compounds
• Artemisinin Compounds
• Other Drug Types

By Malaria Type
• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Malarie
• Plasmodium Ovale

By Mechanism of Action
• Treatment for Malaria
• Prevention from Malaria

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.